Upside case
Bull case
$176+49.5%
A would need investors to value it at roughly 29x earnings — about 10x more generous than today's 20x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Agilent Technologies, Inc. (A) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
38
analysts
29 bullish · 1 bearish · 38 covering A
Strong Buy
1
Buy
28
Hold
8
Sell
1
Strong Sell
0
Consensus Target
$166
+41.2% vs today
Scenario Range
$81 – $176
Model bear to bull value window
Coverage
38
Published analyst ratings
Valuation Context
19.7x
Forward P/E · Market cap $33.3B
A price targets
Three scenarios for where A stock could go
Current
~$118
Confidence
64 / 100
Updated
May 1, 2026
Where we are now
Current · $118
Bear
$81
Base
$146
Bull
$176
Market caseClosest to today
Base case
$146+24.5%
At 25x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$81-31.3%
If investor confidence fades or macro conditions deteriorate, a 6x multiple contraction could push A down roughly 31% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Agilent Technologies, Inc.
A · NYSEHealthcareMedical - Diagnostics & ResearchOctober year-end
Agilent Technologies is a life sciences and diagnostics company that provides analytical instruments, software, and services to laboratories worldwide. It generates revenue primarily from selling laboratory instruments and consumables (~70% of sales) and related services (~30%), with its Life Sciences & Applied Markets segment contributing about 60% of revenue and Diagnostics & Genomics around 40%. The company's competitive advantage lies in its deep application expertise across multiple scientific domains—particularly in chromatography and mass spectrometry—and its sticky customer relationships built on complex, integrated workflow solutions.
Market Cap
$33.3B
Revenue TTM
$7.1B
Net Income TTM
$1.3B
Net Margin
18.3%
A Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
+2.6%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Last 4 Quarters
EPS beats: 3 of 4Q2 2025
EPS
$1.31/$1.26
Revenue
$1.7B/$1.6B
Q3 2025
EPS
$1.37/$1.37
Revenue
$1.7B/$1.7B
Q4 2025
EPS
$1.59/$1.58
Revenue
$1.8B/$1.8B
Q1 2026
EPS
$1.36/$1.37
Revenue
$1.8B/$1.8B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q2 2025 | $1.31/$1.26 | +4.0% | $1.7B/$1.6B | +2.5% |
| Q3 2025 | $1.37/$1.37 | +0.0% | $1.7B/$1.7B | +3.2% |
| Q4 2025 | $1.59/$1.58 | +0.4% | $1.8B/$1.8B | +0.4% |
| Q1 2026 | $1.36/$1.37 | -0.7% | $1.8B/$1.8B | -0.5% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$7.4B
+4.6% YoY
FY2
$7.8B
+5.0% YoY
EPS Outlook
FY1
$5.31
+16.9% YoY
FY2
$5.69
+7.2% YoY
Trailing FCF (TTM)$993M
FCF Margin: 14.1%
Next Earnings
May 27, 2026
Expected EPS
$1.40
Expected Revenue
$1.8B
A beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
A Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $6.9B
Product Mix
Latest annual revenue by segment or product family
Agilent CrossLab
41.9%
+76.9% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Americas
40.4%
+9.1% YoY
Tap, hover, or focus a slice to inspect segment detail.
Agilent CrossLab is the largest disclosed segment at 41.9% of FY 2025 revenue, up 76.9% YoY.
Americas is the largest reported region at 40.4%, up 9.1% YoY.
A Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Undervalued
Fair value est. $145 — implies +27.1% from today's price.
Upside to Fair Value
27.1%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
A
25.7x
vs
S&P 500
25.1x
In line with benchmark
vs Healthcare Trailing P/E
A
25.7x
vs
Healthcare
22.2x
+16% premium
vs A 5Y Avg P/E
Today
25.7x
vs
5Y Average
31.8x
19% discount
Forward PE
19.7x
S&P 500
19.1x
+3%
Healthcare
18.8x
+5%
5Y Avg
—
—
Trailing PE
25.7x
S&P 500
25.1x
+2%
Healthcare
22.2x
+16%
5Y Avg
31.8x
-19%
PEG Ratio
1.75x
S&P 500
1.72x
+2%
Healthcare
1.53x
+14%
5Y Avg
—
—
EV/EBITDA
19.7x
S&P 500
15.2x
+30%
Healthcare
14.0x
+41%
5Y Avg
23.8x
-17%
Price/FCF
28.9x
S&P 500
21.1x
+37%
Healthcare
18.6x
+56%
5Y Avg
32.5x
-11%
Price/Sales
4.8x
S&P 500
3.1x
+53%
Healthcare
2.8x
+71%
5Y Avg
6.0x
-20%
Dividend Yield
0.84%
S&P 500
1.87%
-55%
Healthcare
1.42%
-41%
5Y Avg
0.67%
+26%
| Metric | A | S&P 500 | Healthcare | 5Y Avg A |
|---|---|---|---|---|
| Forward PE | 19.7x | 19.1x | 18.8x | — |
| Trailing PE | 25.7x | 25.1x | 22.2x+16% | 31.8x-19% |
| PEG Ratio | 1.75x | 1.72x | 1.53x+14% | — |
| EV/EBITDA | 19.7x | 15.2x+30% | 14.0x+41% | 23.8x-17% |
| Price/FCF | 28.9x | 21.1x+37% | 18.6x+56% | 32.5x-11% |
| Price/Sales | 4.8x | 3.1x+53% | 2.8x+71% | 6.0x-20% |
| Dividend Yield | 0.84% | 1.87% | 1.42% | 0.67% |
A trades above S&P 500 benchmarks on 3 of 6 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolA Financial Health
Verdict
Strong
A generates $993M in free cash flow at a 14.1% margin — 13.5% ROIC signals a durable competitive advantage · returns 2.1% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$7.1B
Revenue Growth
TTM vs prior year
+8.1%
Gross Margin
Gross profit as a share of revenue
38.8%
Operating Margin
Operating income divided by revenue
20.6%
Net Margin
Net income divided by revenue
18.3%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$4.54
Free Cash Flow (TTM)
Cash generation after capex
$993M
FCF Margin
FCF as share of revenue — the primary cash quality signal
14.1%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
13.5%
ROA
Return on assets, trailing twelve months
10.1%
Cash & Equivalents
Liquid assets on the balance sheet
$1.8B
Net Debt
Total debt minus cash
$1.6B
Debt Serviceability
Net debt as a multiple of annual free cash flow
1.6× FCF
~1.6 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
18.7%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
2.1%
Dividend
0.8%
Buyback
1.3%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$425M
Dividend / Share
Annualized trailing dividend per share
$0.99
Payout Ratio
Share of earnings distributed as dividends
21.6%
Shares Outstanding
Declining as buybacks retire shares
284M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageA Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
High Risk
Inflation & Interest Rates
High inflation can trigger central bank rate hikes, raising borrowing costs and squeezing margins. For a company with significant debt, this can erode profitability and increase default risk.
High Risk
Political & Regulatory Risk
Sudden policy shifts, trade disputes, or regulatory enforcement can disrupt operations or increase compliance costs. For companies exposed to international markets, geopolitical tensions can materially affect revenue streams.
Medium
Financial Leverage
High Debt-to-Equity or Net Debt-to-EBITDA ratios amplify earnings volatility. In downturns, leverage can trigger margin calls or forced asset sales, impacting share price.
Medium
Management Decisions
Poor strategic choices, such as failed acquisitions or cost‑cutting missteps, can erode shareholder value. Leadership turnover or misaligned incentives may lead to operational inefficiencies.
Lower
Liquidity Risk
Low trading volume can make it difficult to exit positions at fair value, especially during market stress. Thinly traded stocks may experience wider bid‑ask spreads and higher transaction costs.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why A Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Index Gains of 20% or More
Major stock indices have historically risen at least 20% during sustained bull markets, indicating strong market momentum. Such a rise reflects broad investor confidence and can drive individual stock prices upward.
Central Bank Interest Rate Cuts
Expectations of interest rate cuts lower borrowing costs for companies and consumers, reducing discount rates for future earnings. This environment can justify higher stock valuations and stimulate economic activity.
Declining Inflation Driven by Supply Chain Resolution
A falling inflation rate, especially when attributed to resolving supply chain issues rather than a weakening economy, supports the bull case. Lower inflation reduces cost pressures and can improve corporate profit margins.
AI‑Driven Productivity and Growth
Innovations in Artificial Intelligence can boost productivity and create new growth opportunities for companies. AI advancements are a key catalyst for long‑term earnings expansion.
Positive Investor Sentiment and Capital Flows
Strong investor sentiment, demand for stocks exceeding supply, and significant capital inflows—including retail investors and corporate buybacks—can fuel a bull market. These flows often reinforce upward price momentum.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
A Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$117.53
52W Range Position
24%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$104.36
+12.6% from the low
52-Week High
$160.27
-26.7% from the high
1 Month
+2.29%
3 Month
-9.34%
YTD
-14.8%
1 Year
+8.5%
3Y CAGR
-4.1%
5Y CAGR
-2.5%
10Y CAGR
+11.1%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
A vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
19.7x
vs 20.7x median
-5% below peer median
Revenue Growth
+4.6%
vs +4.1% median
+13% above peer median
Net Margin
18.3%
vs 14.9% median
+23% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
A A Agilent Technologies, Inc. | $33.3B | 19.7x | +4.6% | 18.3% | Buy | +41.2% |
WAT WAT Waters Corporation | $20.4B | 23.8x | +45.4% | 11.9% | Hold | +17.5% |
TMO TMO Thermo Fisher Scientific Inc. | $173.5B | 18.8x | +4.1% | 15.2% | Buy | +40.3% |
DHR DHR Danaher Corporation | $123.6B | 20.7x | +1.8% | 14.9% | Buy | +41.4% |
BRK BRKR Bruker Corporation | $5.8B | 18.0x | +10.4% | -0.3% | Buy | +37.1% |
MTD MTD Mettler-Toledo International Inc. | $26.5B | 28.0x | +3.8% | 21.6% | Hold | +14.5% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
A Dividend and Capital Return
A returns capital mainly through $425M/year in buybacks (1.3% buyback yield), with a modest 0.84% dividend — combining for 2.1% total shareholder yield. The dividend has grown for 10 consecutive years.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
2.1%
Dividend + buyback return per year
Buyback Yield
1.3%
Dividend Yield
0.84%
Payout Ratio
21.6%
How A Splits Its Return
Div 0.84%
Buyback 1.3%
Dividend 0.84%Buybacks 1.3%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.99
Growth Streak
Consecutive years of dividend increases
10Y
3Y Div CAGR
-11.3%
5Y Div CAGR
6.6%
Ex-Dividend Date
—
Payment Cadence
Quarterly
4 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$425M
Estimated Shares Retired
4M
Approx. Share Reduction
1.3%
Shares Outstanding
Current diluted share count from the screening snapshot
284M
At 1.3%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.51 | — | — | — |
| 2025 | $0.74 | -22.2% | 1.0% | 1.7% |
| 2024 | $0.96 | +4.9% | 3.0% | 3.8% |
| 2023 | $0.91 | -14.5% | 1.9% | 2.7% |
| 2022 | $1.06 | +37.2% | 2.7% | 3.3% |
FAQ
7 questionsA Investor Questions
Common questions answered from live analyst data and company financials.
01Is Agilent Technologies, Inc. (A) stock a buy or sell in 2026?
Agilent Technologies, Inc. (A) is rated Buy by Wall Street analysts as of 2026. Of 38 analysts covering the stock, 29 rate it Buy or Strong Buy, 8 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $166, implying +41.2% from the current price of $118. The bear case scenario is $81 and the bull case is $176.
02What is the A stock price target for 2026?
The Wall Street consensus price target for A is $166 based on 38 analyst estimates. The high-end target is $180 (+53.2% from today), and the low-end target is $140 (+19.1%). The base case model target is $146.
03Is Agilent Technologies, Inc. (A) stock overvalued in 2026?
A trades at 19.7x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Agilent Technologies, Inc. (A) stock in 2026?
The primary risks for A in 2026 are: (1) Inflation & Interest Rates — High inflation can trigger central bank rate hikes, raising borrowing costs and squeezing margins. (2) Political & Regulatory Risk — Sudden policy shifts, trade disputes, or regulatory enforcement can disrupt operations or increase compliance costs. (3) Financial Leverage — High Debt-to-Equity or Net Debt-to-EBITDA ratios amplify earnings volatility. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Agilent Technologies, Inc.'s revenue and earnings forecast?
Analyst consensus estimates A will report consensus revenue of $7.4B (+4.6% year-over-year) and EPS of $5.31 (+16.9% year-over-year) for the upcoming fiscal year. The following year, analysts project $7.8B in revenue.
06When does Agilent Technologies, Inc. (A) report its next earnings?
Agilent Technologies, Inc. is expected to report its next earnings on approximately 2026-05-27. Consensus expects EPS of $1.40 and revenue of $1.8B. Over recent quarters, A has beaten EPS estimates 83% of the time.
07How much free cash flow does Agilent Technologies, Inc. generate?
Agilent Technologies, Inc. (A) generated $993M in free cash flow over the trailing twelve months — a free cash flow margin of 14.1%. A returns capital to shareholders through dividends (0.8% yield) and share repurchases ($425M TTM).